Lessons Learned: This phase II trial evaluated the efficacy of erlotinib for patients with non-small cell lung cancer with leptomeningeal metastasis. The 17 cerebrospinal fluid specimens that were available for epidermal growth factor receptor mutation analysis were all negative for the resistance-conferring T790M mutation. The cytological objective clearance rate was 30.0% (95% confidence interval: 11.9%-54.3%). The median time to progression was 2.2 months. The rate of cerebrospinal fluid penetration among these patients was equivalent to those in previous reports regarding leptomeningeal metastasis.
Background: Leptomeningeal metastases (LM) occur in approximately 5% of patients with non-small cell lung cancer (NSCLC) and are associated with a poor prognosis. However, no prospective study has identified an active chemotherapeutic drug in this setting.
Methods: Patients were considered eligible to receive erlotinib if they had NSCLC with cytologically confirmed LM. The objective cytological clearance rate, time to LM progression (TTP), overall survival (OS), quality of life outcomes, and pharmacokinetics were analyzed. This study was closed because of slow accrual at 21 of the intended 32 patients (66%).
Results: Between December 2011 and May 2015, 21 patients (17 with activating epidermal growth factor receptor [EGFR] mutations) were enrolled. The 17 cerebrospinal fluid specimens available were all negative for the T790M mutation, which confers erlotinib resistance. The clearance rate was 30.0% (95% confidence interval [CI]: 11.9%-54.3%), the median TTP was 2.2 months, and the median OS was 3.4 months. Significantly longer TTP and OS times were observed in patients with mutant EGFR (p = .0113 and p < .0054, respectively). The mean cerebrospinal fluid penetration rate was 3.31% ± 0.77%. There was a good correlation between plasma and cerebrospinal fluid (CSF) concentrations, although there was no clear correlation between pharmacokinetic parameters and clinical outcome.
Conclusion: Erlotinib was active for LM and may be a treatment option for patients with EGFR-mutated NSCLC and LM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108053 | PMC |
| http://dx.doi.org/10.1634/theoncologist.2020-0640 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Iatrogenic pseudoaneurysm formation of the anterior cerebral artery following placement of an external ventricular drain: illustrative case.
J Neurosurg Case Lessons
January 2025
Department of Neurological Surgery, Cooper University Health Care, Camden, New Jersey.
Background: External ventricular drains (EVDs) provide an invaluable diagnostic method for accessing cerebrospinal fluid and therapeutically treating elevated intracranial pressure. Although complications including hemorrhage and infection have been well documented, the formation of iatrogenic pseudoaneurysms following EVD placement has rarely been reported. The authors present a case of this exceedingly rare complication of iatrogenic pseudoaneurysm formation following EVD placement.
View Article and Find Full Text PDFCommunicating hydrocephalus following stereotactic radiosurgery for periventricular meningiomas: illustrative cases.
J Neurosurg Case Lessons
January 2025
Victor Horsley Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom.
Background: Stereotactic radiosurgery (SRS) is a well-established option for the management of intracranial tumors, including meningiomas. Although valued for its low invasiveness and precision, it still carries a risk of complications. Communicating hydrocephalus is a serious, albeit rarely reported, complication of SRS.
View Article and Find Full Text PDFVentriculoperitoneal shunt in the treatment of cryptococcal meningitis with intracranial hypertension.
J Infect Dev Ctries
December 2024
Department of Neurosurgery, The third affiliated hospital, Sun Yat-Sen University, Guangzhou, China.
Introduction: Cryptococcal meningitis (CM) combined with intracranial hypertension is associated with a poor prognosis. This study aimed to investigate the therapeutic efficacy and prognostic factors of ventriculoperitoneal (VP) shunt in non-human immunodeficiency virus (HIV) CM patients with intracranial hypertension.
Methodology: A total of 136 non-HIV CM patients with intracranial hypertension treated in our hospital from July 2010 to December 2019 were retrospectively included.
Bilateral facial nerve palsy in a patient with West Nile neuroinvasive disease.
J Infect Dev Ctries
December 2024
University Clinic for Infectious and Tropical Diseases of the University Clinical Centre of Serbia, Belgrade, Serbia.
Introduction: Bilateral facial nerve palsy (FNP) is a rare condition that is idiopathic in only 20%. FNP is the most common cranial neuropathy in West Nile neuroinvasive disease (WNND) but is usually unilateral and only a few cases of bilateral FNP have been reported.
Case: We present a case of a 65-year-old woman with confirmed WNND and simultaneous bilateral FNP.
Acute leukemia in children: evaluating the necessity of routine biochemical analysis of cerebrospinal fluid.
Eur J Pediatr
January 2025
Pediatric Oncology and Hematology, Caen University Hospital, Avenue de La Côte de Nacre, 14000, Caen, France.
Unlabelled: Biochemical analyses of cerebrospinal fluid (CSF) are routinely performed at diagnosis in many pediatric oncology and hematology centers when acute leukemia is diagnosed. However, the clinical relevance of these analyses remains unclear. We conducted a retrospective analysis of biochemical CSF data from children diagnosed with acute leukemia at two French hospitals between 2016 and 2023 assessing the results in relation to the presence or absence of leukemic neuromeningeal involvement and the correlation between cytological and biochemical analyses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!